Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

This is a retrospective study (reviewing past medical records) comparing two types of conditioning chemotherapy regimens used before a second stem cell transplant in multiple myeloma patients who relapsed after their first transplant. It compares the combination of bortezomib, bendamustine, and melphalan versus melphalan alone, to see which approach led to better outcomes. **You may be eligible if...** - You have multiple myeloma - You had a first relapse after a prior autologous stem cell transplant (using your own stem cells) - You received a second autologous stem cell transplant at the specified hospital (UUH) as part of second-line treatment - Your conditioning before the second transplant used either the combination regimen or melphalan alone **You may NOT be eligible if...** - You had a tandem (double) transplant during first or second line treatment - You received a donor (allogeneic) stem cell transplant - Your medical records are too incomplete to analyze the required data points Talk to your doctor to see if this trial is right for you.